Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Active, not recruiting · NCT04409639 · Registry updated 2026-07-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-07-21 | NCT04409639 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| University of Utah | 319 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fred Hutchinson Cancer Research Center | Seattle | United States | 71 |
| Huntsman Cancer Institute at University of Utah | Salt Lake City | United States | 28 |
| Oregon Health and Science University | Portland | United States | 382 |